Heart failure hospitalization: Why this moment matters

Hospitalization provides an opportunity for physicians to optimize heart failure treatment to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve outcomes for patients living with heart failure.

What is chronic heart failure?

- Heart failure (HF) is a progressive disease where the heart cannot pump enough blood around the body. This, in most cases, happens because the heart muscle responsible for the pumping action weakens or stiffens over time¹.
- HF can be life threatening if neglected and under-treated, as damage occurs to the heart

 even if no symptoms are present.
- There are two main types of HF: reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF)². About half of all HF patients have reduced ejection fraction³.
- There is currently no cure for HF, leading to the death of around half of all patients within five years of diagnosis^{4,5}.
- The goals of treatment in patients with HF are to improve their clinical status, functional capacity and quality of life, prevent hospital admission and reduce mortality⁶.
- HF is approaching epidemic proportions, affecting at least 26 million people globally⁷.

What is an acute heart failure episode?

- Acute heart failure (AHF) is the sudden and acute worsening of the signs and symptoms of heart failure.
- As an AHF episode approaches, patients become severely breathless and incapacitated, they rapidly gain weight due to fluid build-up in the lungs and around the body⁸; this is often compared to the sensation of drowning⁹.
- Every AHF episode contributes to a downward spiral of worsening health and damage to vital organs, such as the heart and kidneys, which decreases the chance of the patient surviving another episode^{4,10,11}.
- There is currently no approved treatment for acute heart failure.



Heart failure as a progressive disease with deterioration of cardiac function and quality of life. Adapted from Mesquita *et al.*, *International Journal of Cardiovascular Sciences*. 2017;30(1):81-90¹²



1

The burden of hospitalization

- HF is the number one reason for hospitalization in people over 65 years¹³ with nearly 1 million patients hospitalized every year in US and Europe¹⁴.
- 83 percent of HF patients are hospitalized due to an AHF episode at least once, and nearly half (43%) are hospitalized at least four times¹⁵.
- Hospital admission for HF provides a key opportunity to optimize HF therapy according to guidelines is critical to reduce the likelihood of another acute episode or dying¹⁶.

The impact of hospitalization on patients and their caregivers

- An average length of stay in hospital for a HF patient is five to 10 days¹⁷.
- The outlook for HF patients following hospitalization is poor. In the first 30 days after leaving hospital, one in four face readmission¹⁸ and up to one in 10 are likely to die¹⁹.
- The transition from hospital care, where they have been closely supervised, to care at home, where they are less frequently monitored, is thought to increase the risk of a sudden decline in health²⁰.
- Living with HF, including hospitalization, places a huge burden on the patient, but also their support network. A recent survey of caregivers found that half did not feel prepared or supported in their role, and one in 10 (13%) have quit their jobs to provide care for a person with HF²¹.

The impact of hospitalization on healthcare systems

- HF places a huge financial burden on global healthcare systems²².
- In the United States, the majority of HF-related costs can be attributed to in-hospital care (60%), with the remainder of costs attributed to nursing homes (13%), home health care (9%), HF medication (9%) and physicians (7%)²³.

References

¹⁴ Ambrosy A, Fonarow G, Butler J. *et al.*, The global health and economic burden of hospitalizations for heart failure. *J Am Coll Cardio*. 2014, 63 (12), 1123-33.



¹ Mayo Clinic. Heart Failure. Available at: https://www.mayoclinic.org/diseases-conditions/heart-failure/symptomscauses/syc-20373142 [Last accessed August 2018]

² European Society of Cardiology. Ejection Fraction Heart Failure Measurement. Available at:

https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failuremeasurement [Last accessed August 2018]

³ Owan TE, Hodge DO, Herges RM, *et al.* Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med.* 2006;355:251-259.

⁴ Zannad F., et al., Heart failure burden and therapy. Europace 2009, 11; v1-v9.

⁵ Loehr LR., *et al.*, Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). *Am J Cardiol*. 2008;101(7):1016-1022.

⁶ Ponikowski P, *et al.*, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. *Eur Heart J.* 2016; 37(27):2129–2200,

⁷ Savarese G, Lund LH. Global Public Health Burden of Heart Failure. *Cardiac Failure Review*. 2017;3 (1):7-11.

⁸ Mosterd A, Hoes, A, Clinical epidemiology of heart failure. *Heart* 2007;93:1137-1146.

⁹ Irish Heart Foundation. Step by Step through Heart Failure. Available at: http://irishheart.ie/wp-content/uploads/2016/12/Heart-Failure-Step-by-Step.pdf. [Last accessed: August 2018]

¹⁰ Gheorghiade M, Pang P., Acute heart failure syndromes. J Am Coll Cardio. 2009; 53 (7):557-73.

¹¹ Gheorghiade M., *et al.*, Rehospitalization for heart failure: problems and perspectives. *J Am Coll Cardio*. 2013, 61(4):391-403.

¹² Mesquita ET., *et al.*, Understanding Hospitalization in Patients with Heart Failure. *International Journal of Cardiovascular Sciences*. 2017;30(1):81-90.

¹³ Azad N, Lemay G. Management of chronic heart failure in the older population. *Journal of Geriatric Cardiology: JGC*. 2014;11(4):329-337.

¹⁵ Yancy CW., et al., 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013; 62(16):e147-e239.

¹⁶ Maggioni, AP., et al., Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013 Oct; 15(10): 1173-84.

¹⁷ Ponikowski P et al., 2014. Heart failure. Preventing disease and death worldwide. Available at:

https://www.escardio.org/static file/Escardio/Subspecialty/HFA/WHFA-whitepaper-15-May-14.pdf [Last accessed: July 2018] ¹⁸ Dharmarajan K, Hsieh AF, Lin Z, *et al.*, Diagnoses and Timing of 30-Day Readmissions after Hospitalization For ¹⁹ Diagnoses and Timing of 30-Day Readmissions after Hospitalization For ¹⁰ Diagnoses and Timing of 30-Day Readmissions after Hospitalization For

¹⁹ Bueno H, Ross JS, Wang Y, *et al.*, Trends in Length of Stay and Short-Term Outcomes among Medicare Patients Hospitalized for Heart Failure: 1993–2008. *JAMA*. 2010;303(21):2141-2147.

²⁰ Pascual-Figal D., et al., Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. postdischarge initiation of sacubitril/valsartan. ESC Heart Fail. 2018 Apr;5(2):327-336.

²¹ International Carers. Carers of persons with heart failure: a four nation study. Available at:

http://www.internationalcarers.org/wp-content/uploads/2017/12/IACO-Carers-Infographic-1.pdf [Last accessed: July 2018]

²² Cook C, Cole G, Asaria P., et al., The annual global economic burden of heart failure. Int J Cardiol. 2014.;171(3):368-76.

²³ Braunschweig F, Cowie MR, and Auricchio A, What are the costs of heart failure? *EP Europace*. 2011:13(S2):13– 17.

U NOVARTIS